



23rd Annual Report 2001-2002

u Libran



Dear Shareholders,

It has been a year of restructuring with focus on creating brands worldwide through R & D. True to our mission of serving global health-care needs, with empathy, innovation and technology, we have captured more markets with newer products during the year. A healthy growth of 21% in direct export business was the result of our efforts in this direction. This growth was more important because of the higher component of brand business, as against low value tender business in the earlier years, which has helped us to improve the operating margins.

One of the rare happenings in the industry and in line with our philosophy of "Innovation - The art of creating opportunities and optimizing them," the Life+Care expansion program has yielded great results during the year with the division achieving 85% growth over the previous year. Endowed with the NCDs, the division is now creating a specialty segment for Cardiovascular and Diabetic with a new team of 100 people.

The introduction of the NCDs product "Nimsoft" for Arthritis, specially designed to cure morning stiffness in the patient offers new commitment to introduce research based growth products. Out of the total 16 patents filed so far, 7 have been put into the market successfully and the others are in pipeline to feed the ambitious growth in the coming years. This will enable us to create Global brands through R & D and also ensure our smooth transition in the patent era.

The Civic Award presented to your company recently by Ayubkar Chamber of Commerce for the efforts in the area of community development is dedicated to all your shareholders, for without your support it would not have been possible to achieve this success.

(Signature)

Mumtaz H. Agorwal
Chairman

(Signature)

Ferozullah H. Agorwal
Managing Director

Annual Reports Library

BOARD OF DIRECTORS

Mr. Ramdas B. Agnewal
Chairman

Mr. Paragbhai B. Agnewal
Managing Director

Mr. Madhwarao B. Agnewal
J. Managing Director

Dr. Sridhar Ramdasrao
Director

Mr. Chandrashekhar
Director

Mr. Ramakrishna Rajgopal
Director

Mr. Rajesh M. Agnewal
Director

Dr. Ashwini
Member of the Finance Committee

Mr. Sunil Chaudhary
Member, Board of Directors
Group Management Ltd.

Mr. Ravi Singh
Member, Director, 1999

CHIEF FINANCIAL OFFICER

Mr. M. K. Srinivas

AUDITORS

Major & Partners Accountants
Chartered Accountants

REGISTERED OFFICE

"Shanti Krishi", 8A, Ganga Indraprastha Area,
Chennai, Tamil Nadu
Pincode - 600 027

Annual Reports Library

CONTENTS

Director's Report	2
Executive Corporate Review page	3
Management Discussion & Analysis	15
Auditors' Report	16
Balance Sheet	20
Profit & Loss Account	21
Schedule forming part of Accounts	22
Notes to Accounts	23
Cash Flow Statement	24
Section 212 Statement Relating to Subsidiary Companies	27
Auditors' Report on Consolidated Accounts	30
Consolidated Accounts	40
Statement of Shareholders	42

Letter from the Chairman

Dear Directors and Shareholders, I am pleased to present this 2001 Annual Report on the business and operations of your Company for the year ended March 31, 2002.

FINANCIAL PERFORMANCE

	(Rs. lakh)	
	Year ended 31st March, 2002	Year ended 31st March, 2001
Income	1108	624
Trade before Depreciation & Taxation	899	542
Less: Depreciation	498	174
Profit before Taxation	265	168
Less: Provision for Taxation	41	40
Net Profit after Tax	328	244
Acc. Balance for	170	89
PROFIT AVAILABLE FOR		
APPROPRIATION AND	498	168
APPROPRIATION AND DIVIDEND		

a) Interim Proposed Dividend :-		
- on Paid-up Share	25	25
- on Equity Shares	67	175
b) Dividend Payable on Demand	498	21
c) Dividend Reserve	25	168
d) Balance for	474	264
TOTAL	498	168

It was a year of transformation with focus on building capacity worldwide. Besides, presently and future business of various products has contributed in various growth, which has led them to expansion in the industry in terms of manufacturing sites. The company, wherever it is (USA, Malaysia, Singapore) of the Company's spread through its chain of stores, all over Malaysia and elsewhere, it is now willing to bring further expansion beyond building.

Moreover, the 10% shareholding has been very much with 1% and 10% shareholding in various other companies under the same. It is also true that a growth of 10% or higher, if not registered in the field of their business, it is a success.

The Company's performance is reflected in the expansion of just 10 years, looking at large investments, particularly, which has resulted in many projects with 10%. This has resulted in the reduction of the income, created further transformation in other business.

The focus on financial discipline has helped the Company to maintain operating margins by the share points, with the highest per share, higher interest income and reduced depreciation charge has brought down the net profit for the year under review.

With further expansion of the Company's expanding regions of Malaysia and Indonesia, and 100% of the share, the company has been able to expand its business, which has resulted in the expansion of the company's business, which has resulted in the expansion of the company's business.

MANAGEMENT

The Directors' remuneration is decided for the year by 10% on Equity Shares subject to certain conditions and 10% on Preference Shares of the Company.

RESEARCH AND DEVELOPMENT

Our Research and Development team has been the first to develop "Global Thermal" for Airborne and Grounding during the year. The company's research and development team has been able to develop a new product, which has resulted in the expansion of the company's business. The company's research and development team has been able to develop a new product, which has resulted in the expansion of the company's business. The company's research and development team has been able to develop a new product, which has resulted in the expansion of the company's business.

OTHER FINANCIAL OPERATIONS

Our Company's subsidiary in Malaysia has performed reasonably well during the year. The General Assembly of the Company has been able to expand the company's business, which has resulted in the expansion of the company's business. The company's research and development team has been able to develop a new product, which has resulted in the expansion of the company's business.



UNIT 1

1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 2679, 26

Keywords: social support; coping strategies; self-esteem

Public Health Practice 1999, 4(1):1-10

Particulars	As per the company	Inspected by Prakash Rao
Particulars: Expenses	2,479	2,488
Particulars: Expenses	1,668	1,668
Particulars: Expenses	940	940
Particulars: Expenses	2,479	2,479
Particulars: Expenses	940	940
Total	11,799	11,800
Less : Credit amount	1,500	-
Net amount received	10,299	-

1000

The results of the other surveys of the subsidiary company, along with the statement provided in Article 112 of the Companies Act, 1956, are annexed.

1000

M. Distribution of Capital: No Transfer of Assets and no Modification of Control. Supporters of the Company split by children and family groups, after the parents' death.

The magazine simply, at three Dollars (30p) hides out in the Republic of Congo, Government territory, just in the Arms embargo.

[illegible]

1000

This material is prepared under Federal Report, and may
contain information of the Government, and will be subject to

1000

The Company's interest accounted for less than 1% of the total value of the common stock of the Company on July 1, 2014.

1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 26

[illegible]

1. That in the preparation of the annual accounts, the appropriate accounting standards have been followed
2. That the Company has maintained proper accounting and control records in accordance with generally accepted accounting principles and practices and in accordance with the provisions of the Companies Act, 1956, and that the Company has not been convicted under the provisions of the Companies Act, 1956, for mismanagement or for fraud or for any offence relating to the management of the Company or for any offence relating to the preparation of the accounts of the Company or for any offence relating to the management of the Company or for any offence relating to the preparation of the accounts of the Company
3. That the Annual Accounts have been prepared in accordance with the provisions of the Companies Act, 1956, and that the Company has not been convicted under the provisions of the Companies Act, 1956, for mismanagement or for fraud or for any offence relating to the management of the Company or for any offence relating to the preparation of the accounts of the Company or for any offence relating to the management of the Company or for any offence relating to the preparation of the accounts of the Company

Abstract

Impacts on Management Development contributed by the partnership between an MNC and a local management program. The process of CDD collaboration through trials and testing has also helped:

Abstract

The effect of plan Company is to be as represented by the
the results in general, and particularly the development of the
the results in general, and particularly the development of the

Annual Reports Library

environmental education activities. During the year under review, the age groups and the gender targets sought were completed in all projects in the country where more than 2000 people were registered and about 1000 of them have undergone numerous activities.

In compliance of these social efforts, Socially Creative of Comptech and Industry has obtained in the Company the prestigious Global standard in the area of citizenship's development for 2000-01. The entire highlights of the annual reports during this Group Companies' activities (Johnson, Johnson and Co. Inc.)

DISCLOSURE OF PARTICULARS

As required by the Companies' Disclosure of Particulars in the Report of Board of Directors Rules, 1988, the various particulars are given in Annexure.

PARTICULARS OF EMPLOYEES

During the year under review, none of the employees of the Company received remuneration exceeding Rs.10,00,000 under Section 17(1) (vi) of the Companies Act, 1988, are awarded.

COMPANIES' SOCIAL WORK

For further details of the existing Agreements with the Stock Exchanges, or Management Development and Finance

Companies' Board/Board of Directors of Comptech regarding compliance of conditions and Corporate Governance are made a part of the Annual Report.

CONSTITUTION AND APPROVALS

The Directorate is in place of the Board of Directors for the cooperation submitted by the Directors, President, Managing Director, Chairman, Executive Director, Chairman, Joint Venture Company, the Government of India, National Institute of Public and Environmental Health.

The Director is in place of the Board of Directors for the cooperation submitted by the Directors, President, Managing Director, Chairman, Executive Director, Chairman, Joint Venture Company, the Government of India, National Institute of Public and Environmental Health.

The Director is in place of the Board of Directors

DATE DUE TO NEXT ISS. 10-01-1967

1. **Introduction**

During the year 2000-01, the Government approved the following projects as major projects:

- [illegible]

1. **Accepted by:** Internationally recognized experts, most with relevant expertise. Providing additional advice to the risk assessment.

* Regression model: $\ln(\text{Salary}) = 0.0000 + 0.0000 \times \text{Age} + 0.0000 \times \text{Experience} + 0.0000 \times \text{Education} + 0.0000 \times \text{Gender} + 0.0000 \times \text{Married} + 0.0000 \times \text{Single} + 0.0000 \times \text{Divorced} + 0.0000 \times \text{Widowed} + 0.0000 \times \text{Married} + 0.0000 \times \text{Single} + 0.0000 \times \text{Divorced} + 0.0000 \times \text{Widowed}$

- **Revised as of 1/1/13 Update Book Pricing**
- **Revisions to make calculations**

Figure 1

Country	Year	Value
China	2000	1.00
China	2001	1.00
China	2002	1.00
China	2003	1.00
China	2004	1.00
China	2005	1.00
China	2006	1.00
China	2007	1.00
China	2008	1.00
China	2009	1.00
China	2010	1.00
China	2011	1.00
China	2012	1.00
China	2013	1.00
China	2014	1.00
China	2015	1.00
China	2016	1.00
China	2017	1.00
China	2018	1.00
China	2019	1.00
China	2020	1.00
China	2021	1.00
China	2022	1.00
China	2023	1.00
China	2024	1.00
China	2025	1.00
China	2026	1.00
China	2027	1.00
China	2028	1.00
China	2029	1.00
China	2030	1.00
China	2031	1.00
China	2032	1.00
China	2033	1.00
China	2034	1.00
China	2035	1.00
China	2036	1.00
China	2037	1.00
China	2038	1.00
China	2039	1.00
China	2040	1.00
China	2041	1.00
China	2042	1.00
China	2043	1.00
China	2044	1.00
China	2045	1.00
China	2046	1.00
China	2047	1.00
China	2048	1.00
China	2049	1.00
China	2050	1.00
China	2051	1.00
China	2052	1.00
China	2053	1.00
China	2054	1.00
China	2055	1.00
China	2056	1.00
China	2057	1.00
China	2058	1.00
China	2059	1.00
China	2060	1.00
China	2061	1.00
China	2062	1.00
China	2063	1.00
China	2064	1.00
China	2065	1.00
China	2066	1.00
China	2067	1.00
China	2068	1.00
China	2069	1.00
China	2070	1.00
China	2071	1.00
China	2072	1.00
China	2073	1.00
China	2074	1.00
China	2075	1.00
China	2076	1.00
China	2077	1.00
China	2078	1.00
China	2079	1.00
China	2080	1.00
China	2081	1.00
China	2082	1.00
China	2083	1.00
China	2084	1.00
China	2085	1.00
China	2086	1.00
China	2087	1.00
China	2088	1.00
China	2089	1.00
China	2090	1.00
China	2091	1.00
China	2092	1.00
China	2093	1.00
China	2094	1.00
China	2095	1.00
China	2096	1.00
China	2097	1.00
China	2098	1.00
China	2099	1.00
China	2100	1.00
China	2101	1.00
China	2102	1.00
China	2103	1.00
China	2104	1.00
China	2105	1.00
China	2106	1.00
China	2107	1.00
China	2108	1.00
China	2109	1.00
China	2110	1.00
China	2111	1.00
China	2112	1.00
China	2113	1.00
China	2114	1.00
China	2115	1.00
China	2116	1.00
China	2117	1.00
China	2118	1.00
China		

1. **Identify the main topic of the text.**
 2. **Summarize the main points of the text.**
 3. **Identify the author's purpose in writing the text.**
 4. **Identify the author's tone in writing the text.**
 5. **Identify the author's bias in writing the text.**
 6. **Identify the author's audience in writing the text.**
 7. **Identify the author's style in writing the text.**
 8. **Identify the author's structure in writing the text.**
 9. **Identify the author's language in writing the text.**
 10. **Identify the author's organization in writing the text.**

Figure 1

Figure 1

1. **Introduction**
 2. **Methodology**
 3. **Results**
 4. **Discussion**
 5. **Conclusion**
 6. **References**
 7. **Appendix**
 8. **Figure 1**
 9. **Figure 2**
 10. **Figure 3**
 11. **Figure 4**
 12. **Figure 5**
 13. **Figure 6**
 14. **Figure 7**
 15. **Figure 8**
 16. **Figure 9**
 17. **Figure 10**
 18. **Figure 11**
 19. **Figure 12**
 20. **Figure 13**
 21. **Figure 14**
 22. **Figure 15**
 23. **Figure 16**
 24. **Figure 17**
 25. **Figure 18**
 26. **Figure 19**
 27. **Figure 20**
 28. **Figure 21**
 29. **Figure 22**
 30. **Figure 23**
 31. **Figure 24**
 32. **Figure 25**
 33. **Figure 26**
 34. **Figure 27**
 35. **Figure 28**
 36. **Figure 29**
 37. **Figure 30**
 38. **Figure 31**
 39. **Figure 32**
 40. **Figure 33**
 41. **Figure 34**
 42. **Figure 35**
 43. **Figure 36**
 44. **Figure 37**
 45. **Figure 38**
 46. **Figure 39**
 47. **Figure 40**
 48. **Figure 41**
 49. **Figure 42**
 50. **Figure 43**
 51. **Figure 44**
 52. **Figure 45**
 53. **Figure 46**
 54. **Figure 47**
 55. **Figure 48**
 56. **Figure 49**
 57. **Figure 50**
 58. **Figure 51**
 59. **Figure 52**
 60. **Figure 53**
 61. **Figure 54**
 62. **Figure 55**
 63. **Figure 56**
 64. **Figure 57**
 65. **Figure 58**
 66. **Figure 59**
 67. **Figure 60**
 68. **Figure 61**
 69. **Figure 62**
 70. **Figure 63**
 71. **Figure 64**
 72. **Figure 65**
 73. **Figure 66**
 74. **Figure 67**
 75. **Figure 68**
 76. **Figure 69**
 77. **Figure 70**
 78. **Figure 71**
 79. **Figure 72**
 80. **Figure 73**
 81. **Figure 74**
 82. **Figure 75**
 83. **Figure 76**
 84. **Figure 77**
 85. **Figure 78**
 86. **Figure 79**
 87. **Figure 80**
 88. **Figure 81**
 89. **Figure 82**
 90. **Figure 83**
 91. **Figure 84**
 92. **Figure 85**
 93. **Figure 86**
 94. **Figure 87**
 95. **Figure 88**
 96. **Figure 89**
 97. **Figure 90**
 98. **Figure 91**
 99. **Figure 92**
 100. **Figure 93**
 101. **Figure 94**
 102. **Figure 95**
 103. **Figure 96**
 104. **Figure 97**
 105. **Figure 98**
 106. **Figure 99**
 107. **Figure 100**
 108. **Figure 101**
 109. **Figure 102**
 110. **Figure 103**
 111. **Figure 104**
 112. **Figure 105**
 113. **Figure 106**
 114. **Figure 107**
 115. **Figure 108**
 116. **Figure 109**
 117. **Figure 110**
 118. **Figure 111**
 119. **Figure 112**
 120. **Figure 113**
 121. **Figure 114**
 122. **Figure 115**
 123. **Figure 116**
 124. **Figure 117**
 125. **Figure 118**
 126. **Figure 119**
 127. **Figure 120**
 128. **Figure 121**
 129. **Figure 122**
 130. **Figure 123**
 131. **Figure 124**
 132. **Figure 125**
 133. **Figure 126**
 134. **Figure 127**
 135. **Figure 128**
 136. **Figure 129**
 137. **Figure 130**
 138. **Figure 131**
 139. **Figure 132**
 140. **Figure 133**
 141. **Figure 134**
 142. **Figure 135**
 143. **Figure 136**
 144. **Figure 137**
 145. **Figure 138**
 146. **Figure 139**
 147. **Figure 140**
 148. **Figure 141**
 149. **Figure 142**
 150. **Figure 143**
 151. **Figure 144**
 152. **Figure 145**
 153. **Figure 146**
 154. **Figure 147**
 155. **Figure 148**
 156. **Figure 149**
 157. **Figure 150**
 158. **Figure 151**
 159. **Figure 152**
 160. **Figure 153**
 161. **Figure 154**
 162. **Figure 155**
 163. **Figure 156**
 164. **Figure 157**
 165. **Figure 158**
 166. **Figure 159**
 167. **Figure 160**
 168. **Figure 161**
 169. **Figure 162**
 170. **Figure 163**
 171. **Figure 164**
 172. **Figure 165**
 173. **Figure 166**
 174. **Figure 167**
 175. **Figure 168**
 176. **Figure 169**
 177. **Figure 170**
 178. **Figure 171**
 179. **Figure 172**
 180. **Figure 173**
 181. **Figure 174**
 182. **Figure 175**
 183. **Figure 176**
 184. **Figure 177**
 185. **Figure 178**
 186. **Figure 179**
 187. **Figure 180**
 188. **Figure 181**
 189. **Figure 182**
 190. **Figure 183**
 191. **Figure 184**
 192. **Figure 185**
 193. **Figure 186**
 194. **Figure 187**
 195. **Figure 188**
 196. **Figure 189**
 197. **Figure 190**
 198. **Figure 191**
 199. **Figure 192**
 200. **Figure 193**
 201. **Figure 194**
 202. **Figure 195**
 203. **Figure 196**
 204. **Figure 197**
 205. **Figure 198**
 206. **Figure 199**
 207. **Figure 200**
 208. **Figure 201**
 209. **Figure 202**
 210. **Figure 203**
 211. **Figure 204**
 212. **Figure 205**
 213. **Figure 206**
 214. **Figure 207**
 215. **Figure 208**
 216. **Figure 209**
 217. **Figure 210</**

1000

[illegible]

1. *Journal of the American Medical Association*, 2000; 283: 2689-2695.

The Company will continue to monitor developments in different parts of its business and may decide to acquire other companies and/or assets in the future.

100

Agencia Nacional Contra el Narcotráfico is supported by the Department of Justice and Institute of Peace and Development of the U.S. Ministry of Science & Technology, their efforts to fund the National Narcotics Institute has earned two national awards, as well the recognition of receiving the highest level of funding in the Colombia and regional level. The Institute enjoys a wide research base and has a staff of 100.

- 4. Furniture's development to meet marketing needs
- 5. Development of physical materials to the product requirements

Annual Reports Library

- iv) General trade for various products
- v) Commission for selling products.
- vi) Development work within area of R&D

3. Benefits derived as a result of R&D :-

- i) New free heating formulation very popular and successful in the domestic & export market in the therapeutic area of respiratory, gastrointestinal and skin & conjunct.
- ii) One product and formulae semi-synthetic was developed and marketed in the medicinal market. 16 other products were developed and marketed during the last 5 years.
- iii) General trade was considered for numerous countries within India and throughout the world since 1980 - 2000 in the form of sales.
- iv) Major work in one of the R&D is completed and is likely to be introduced in the Indian market.
- v) Cash returns earned with major products.

4. Future plan of action :-

- i) To develop new products in the cardio-vascular and anti-diabetic range.
- ii) To open up new formulations and develop new potential anti-diabetic products.
- iii) To continue working on R&D and to seek extension of patenting opportunities.
- iv) To carry out clinical trials for new products.

5. Expenditure on R&D :-

- i) Capital : 1100 Lakhs
- ii) Recurring : 40 Lakhs
- iii) Total : 1140 Lakhs
- iv) Total R & D expenditure : 15.4% as a percentage of total turnover

6. Efforts in Ethical, Health, Safety, Technology Absorption, Management and Innovation :-

- i) The Company's Research Group has a group of people working on development of R&D. The Company has developed proprietary technology for investigations and has other drugs in progress. The Research Group has been operational for 10 years. Company is currently under patent namely Polysorb in South Africa. Polysorb is now a trademark in South Africa.

- ii) Benefits derived as a result of the above efforts, e.g. Product Development, Cost Reduction, Product Development, Export Subsidies etc. :-

- a) Cost Reduction was achieved for 2 products namely polysorb tablet & cough syrup with minimum input & maximum.
- b) Cost Savings achieved were to the tune of 5% of sales.
- c) In case of export technology, imported during the last 5 years, reduced from the beginning of the financial year.

The Company has not imported any technology in the form of consultation in the last 5 years.

7. Financial Performance Summary and Outlook :-

- a. Revenue : relating to exports, technology sales, to increase exports, development of new export markets for products and services and support services.

During the previous year, the Company continued to focus on the development of new products and services. The Company is working on new products and has been able to secure an order in India. Products continue.

After the 10th Company's activities in other countries the focus remains on marketing the products in the markets of South East Asia, (e.g. Malaysia) and other countries. The Company's strategy for the last 5 years is to continue to work on the development of new products and services. The Company's strategy for the last 5 years is to continue to work on the development of new products and services.

The steps were taken for developing, testing, approval and launch of products. The Company's strategy for the last 5 years is to continue to work on the development of new products and services.

These activities are contributing to enhance Company's financial and making companies presence into global markets.

8. Total foreign exchange used and earned

	Year ended 31.03.2000 (Rs. in Lakhs)	Year ended 31.03.1999 (Rs. in Lakhs)
a. Turnover	5,400.00	5,000.00
b. Outgo on export or other foreign trade	100.00	100.00

